An interim clinical commissioning policy has been in place since 3 July 2020, defining routine access to remdesivir in the treatment of COVID-19 across the UK, following confirmation of a Conditional Marketing Authorisation (CMA) by the European Medicines Agency (EMA).
Due to increased demand against available supply, clinicians are now asked to apply the full eligibility criteria as set out within the associated Central Alerting System (CAS) alert CEM/CMO/2020/028(U), last published on 3rd September 2020, and listed below.
Clinicians are also asked to adhere to a standard treatment course of 5 days.
Given the links to covid-19 we have sent this alert to a broader mailing list than would usually receive a Supply Disruption Alert of this type.
Please note that no response is required via the CAS website to this alert.